Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imagion BiosystemsASX:IBX 3-Year EPS without NRI Growth Rate is 64.20% as of Jun. 2026, which is 47% above its 10-year median of 43.55. The stock has 4 warning signs investors should review. Among 160 Medical Diagnostics & Research companies, Imagion Biosystems ranks better than 91.25% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 64.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 42.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of Imagion Biosystems was 64.20% per year. The lowest was -15.30% per year. And the median was 43.55% per year.
Imagion Biosystems (ASX:IBX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Imagion Biosystems 3-Year EPS without NRI Growth Rate Related Terms
ASX:IBX vs TMO, DHR, NTRA: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Imagion Biosystems's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's 3-Year EPS without NRI Growth Rate falls into.
Imagion Biosystems 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 64.20% mean?
Imagion Biosystems (ASX:IBX) has a 3-Year EPS without NRI Growth Rate of 64.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Imagion Biosystems and its competitors. This is 47% above median its historical median of 43.55. According to the industry distribution chart, Imagion Biosystems ranks #14 out of 160 companies in the Medical Diagnostics & Research industry, placing it in the top 8.7%.
Is Imagion Biosystems' 3-Year EPS without NRI Growth Rate too high?
Imagion Biosystems' current 3-Year EPS without NRI Growth Rate of 64.20% is 47% above median its 10-year median of 43.55. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 11.85. Imagion Biosystems' value of 64.20% is 441.8% above this industry median. Based on the distribution chart, Imagion Biosystems ranks #14 out of 160 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Imagion Biosystems' 3-Year EPS without NRI Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #14 out of 160 companies for 3-Year EPS without NRI Growth Rate. This places Imagion Biosystems in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 11.85. Imagion Biosystems' value of 64.20% is 441.8% above this benchmark. While the company's 10-year median is 43.55 vs. the industry median of 11.85, Imagion Biosystems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 11.85, based on 160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imagion Biosystems's current 3-Year EPS without NRI Growth Rate of 64.20% is 441.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Imagion Biosystems and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 11.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current 3-Year EPS without NRI Growth Rate is 64.20%, which is 47% above median its own 10-year median of 43.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 99.3% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 64.20%, which is 47% above median its 10-year median of 43.55 and 441.8% above the Medical Diagnostics & Research industry median of 11.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current 3-Year EPS without NRI Growth Rate is 64.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IBX has been successfully added to your 
